Normal view

There are new articles available, click to refresh the page.
Before yesterdayGreen Market Report

Federal Court Orders RAW to Stop Making False Claims About Papers, Foundation

10 February 2023 at 11:53

The maker of Raw Rolling Papers will have to pivot production by the end of spring to comply with a federal court order telling the company to stop making false claims about its organic hemp line and a nonexistent charitable foundation.

Raw’s competitor Republic Brands took the company to court alleging that Raw’s labels included false information. The owner of a suite of rolling papers that include OCB and Top branded papers eventially obtained the permanent injunction against RAW’s distributing arm, HBI International.

On Jan. 31, the United States District Court for the Northern District of Illinois ordered HBI to stop making certain claims about its products and “immediately” cease manufacturing, ordering, or replenishing its inventory with goods that fail to conform to the court’s order.

The injunction order follows a jury’s verdict that HBI, the distributor of rolling paper brands RAW and Juicy Jays, engaged in unfair competition and violated the Illinois Uniform Deceptive Trade Practices Act through its packaging and promotional activities.

According to the findings, HBI marketed its papers as having been made by artisanal craftsman in “Alcoy, Spain,” referred to Alcoy as the “birthplace of rolling papers,” and affixed an “Alcoy” stamp to some of its products.

However, in a Jan. 19 ruling, the court found that HBI “makes no rolling paper in Alcoy, Spain, whatsoever.”

HBI has also claimed on packaging and in interviews that it contributes its funds and sales proceeds to a 501c charity referred to as the “RAW Foundation,” which the court found in a Dec. 6 ruling to be “nonexistent.”

The court enjoined HBI from continuing to state, imply, or suggest that it operates or contributes funds or sales proceeds to a charitable entity or foundation referred to as the “RAW Foundation” or making reference to the “RAW Foundation” in text or images.

The RAW makers must stop production and sales of all promotions and products that use the Alcoy stamp or references the fake foundation, which happens to be much of the current inventory, by the end of May.

The order also permanently prohibits HBI from making any statement or communication, or engaging in any promotion or advertising activity that states, implies, or suggests that:

  • RAW Organic Hemp rolling papers are “unrefined;”
  • RAW Organic Hemp rolling papers are made with natural hemp gum, or that the adhesive used in RAW Organic Hemp rolling papers is made from or contains hemp;
  • RAW Organic Hemp rolling papers are, or ever were, the world’s first or world’s only organic (or organic hemp) rolling papers;
  • The bulk paper used to make RAW Organic Hemp rolling paper products is made in Spain;
  • RAW Organic Hemp rolling papers are made using wind power or are powered by wind;
  • HBI uses or used the center of the hemp stalk for its RAW Organic Hemp rolling papers;
  • HBI or its founder Joshua Kesselman invented rolling paper pre-rolled cones;
  • The OCB Organic Hemp papers are knock-offs, “RAWnabees,” copies, or fake versions of RAW.

The post Federal Court Orders RAW to Stop Making False Claims About Papers, Foundation appeared first on Green Market Report.

Is BioTrack In Play?

10 February 2023 at 10:42

Cannabis track-and-trace company BioTrack, which is owned by Forian (Nasdaq: FORA), filed a 13-D form with the Securities and Exchange Commission demonstrating that the company could be in play.

The 13-D form is filed with the SEC when a person or group acquires more than 5% of a single class of shares for a company. Forian’s document lists the following entities are acquiring shares:

  • Larry Feinberg, founder of Oracle Investment Management is listed as having 5.42% of the shares
  • Oracle Partners L.P. is listed as having 3.74%
  • Oracle Institutional Partners L.P. as having .54%
  • Oracle Ten Fund was .21%
  • Oracle Investment Management, Inc. Employees’ Retirement Plan with .09%
  • The Feinberg Family Foundation with .02%
  • Oracle Associates, LLC with 4.47%
  • Oracle Investment Management, Inc. 4.56%

According to the company’s website, Oracle Investment Management Inc. (OIM) is a fundamental research-driven investment management company that is exclusively focused on the global health care and bioscience industries.

The firm was founded by Larry N. Feinberg in 1993. Feinberg has been a leading investor and securities analyst in the health care industry for more than 30 years.

Forian stock had been on an upswing since the beginning of the year, but on Feb. 3 it began to slide, slipping from $3.70 to roughly $3.08. In the last two days, the stock popped back to close at $3.38 on Thursday.

In December, Forian announced that New York had selected BioTrack as the track-and-trace system for the New York Office of Cannabis Management’s seed-to-sale tracking system. BioTrack software will track cannabis from when it is first planted as a seed to the point of sale to the consumer.

The OCM said it plans to use the BioTrack seed-to-sale traceability system to monitor the movement of cannabis products in the state’s new adult-use cannabis market and continue monitoring in the state’s medical cannabis market.

In November, Forian reported revenue for the third quarter of $7.2 million, an increase of $2.2 million versus the prior year and 10% sequentially over the second quarter of 2022. The net loss for the quarter was $5.1 million, or $0.16 per share, compared to $7.0 million, or $0.22 per share, in the prior year. The adjusted EBITDA for the quarter was negative $2.2 million, compared to negative $4.1 million in the prior year. The company’s cash, cash equivalents, and marketable securities at the end of the quarter were $20.6 million.

At the time, Forian CEO Dan Barton said, “Third quarter 2022 financial results continue to demonstrate significant revenue growth, especially in our healthcare information offerings. This strong revenue growth coupled with the consistency in our cannabis business and the success of our cost management efforts provide the blueprint to reduce Net Loss and become Adjusted EBITDA positive in the second half of 2023.”

The company hasn’t responded yet for a request to comment on the latest filing.

The post Is BioTrack In Play? appeared first on Green Market Report.

The Weekly Stash: February 10, 2023

10 February 2023 at 09:11

The Weekly Stash is a recap of the week’s top business headlines in the cannabis industry for the week ending February 10, 2023.

Canopy Growth Corp. (TSX: WEED) (Nasdaq: CGC) reported slumping revenues on Thursday and signaled a new cost-savings era that includes cutbacks on cultivation and 800 layoffs. Revenue fell by 28% to $101 million in the quarter. Canopy ‘s historical cash burn has swelled its net losses 131% over the year to $266.7 million. Cash and short-term investments fell by a whopping $583 million to $789 million at the end of December from $1,372 million at the end of March 2022.

The acquisition of New York medical cannabis operator Etain by Riv Capital is entering another messy chapter. Scotts Miracle-Gro (NYSE: SMG), owner of the hydroponic company Hawthorne, has filed a lawsuit against Jason Wild and TerrAscend (OTC: TRSSF) claiming they ruined its $175 million investment. Hawthorne is complaining that Wild fought Riv Capital’s plans to buy Etain asking the board to call off the deal and threatening to attain a hemp license in the state in a move to kill the deal. Wild’s position is that Riv Capital overpaid for the property. 

SNDL Inc. (Nasdaq: SNDL) finalized its purchase of Canadian dispensary chain Superette out of bankruptcy, with plans to support the brand and its stores.SNDL will license some of Superette’s IP to Spirit Leaf Ontario for their retail locations, the company said.

In state news,

Over the first three-day weekend of legal recreational marijuana sales in Missouri, medical and adult-use retail sales combined to hit $12.6 million in sales, the state announced. Many shops reported long lines this past Friday. According to the Missouri Department of Health & Senior Services’ Cannabis Division Regulation, the industry sold $8.5 million in recreational cannabis and another $4.1 million in medical marijuana for Feb.3-5, for a grand total of $12,689,965.

In a break from a national trend, a federal judge in Washington state upheld the state’s residency requirement for cannabis business ownership and ruled that the U.S. Constitution’s dormant commerce clause doesn’t apply because marijuana is still federally illegal. U.S. District Judge Benjamin Settle sided with the Washington Liquor and Cannabis Board and tossed a lawsuit filed in 2020 by marijuana investor Todd Brinkmeyer, who had asked the court to rule that Washington’s residency requirement is unconstitutional. 

The start date for Maryland’s upcoming adult-use cannabis market could be as soon as July 1, under the terms of a new legislative bill introduced this week by state lawmakers.

New York has said it will begin cracking down on illegal operators while the state’s Office of Cannabis Management recommended that medical licenses be expanded. The OCM also suggested that medical patients no longer have to register. 

If you haven’t already signed up for the Morning Rise newsletter. It’s free and hits your inbox at 7 am with fresh content – not just a collection of headlines from other outlets. Wake and partake of the GMR Rise.

The post The Weekly Stash: February 10, 2023 appeared first on Green Market Report.

Dispensaries Lure Shoppers with Super Bowl Deals, Events

10 February 2023 at 00:47

Vegas and Rihanna aren’t the only ones benefiting from the Super Bowl sales boosts this weekend.

Marijuana-friendly football fans are expected to restock their stashes ahead of the Sunday night showdown, and cannabis brands are increasing ad spend to include more Super Bowl-related messaging and promotions.

The Saturday and Sunday before last year’s championship match saw a 24% rise in cannabis sales versus the daily average for the rest of February, according to cannabis marketing platform springbig.

The firm reported that “a number” of its dispensary clients have translated that into investing 25% to 30% of their monthly budgets in Super Bowl-related ads, as opposed to 0% to 10% last year.

Arizona dispensaries are also preparing for an influx of tourists and townies looking for party favors and hangover relievers. The game is being held at State Farm Stadium in Glendale, a suburb of Phoenix, which has a seating capacity of more than 63,000.

“We’re looking to even higher sales this year, especially as the Super Bowl takes place in a recreational Arizona for only the second time (and this year, expecting fewer COVID precautions),” a spokesperson for springbig told Green Market Report.

Companies are looking at the opportunity as one to take advantage of. Trulieve, STIIIZY, Wana Brands, and even System of a Down’s bassist Shavo Odadjian – who will be promoting 22Red – will be hosting and participating in events to market their brands.

STIIIZY is also linking up with Weedmaps at the Rolling Stone Live pre-Super Bowl concert to do product giveaways and merchandising activation.

Advertising campaigns are kicking off earlier this time around, too.

Dispensary promotions aligned with “Big Game” messaging started as early as Feb. 1, “whereas last year most brands began Super Bowl messaging only the Thursday or Friday before the game,” according to Fyllo.

Companies with operations in Arizona are using focused messaging strategies due to the overlap with the PGA Tour’s Phoenix Waste Management Open, which happens to be the most packed PGA golf tournament in the world.

Both events are expected to draw huge crowds over the course of the weekend, and due to the overlapping tentpoles, “some advertisers have geared audience strategies to focus more on tourists and out-of-state visitors, informing them of the availability of legal cannabis in Arizona,” Fyllo said.

Around 700,000 people attend the golf event, rounding out a “significant” opportunity to reach new users who are in the state and near the Phoenix market for the weekend, the firm said.

The post Dispensaries Lure Shoppers with Super Bowl Deals, Events appeared first on Green Market Report.

Daily Hit: February 9, 2023

By: Staff
9 February 2023 at 18:30

The Daily Hit

The Daily Hit is a recap of the top financial news stories for February 9, 2023.

On the Site

Canopy Slashes 800 From Payroll After Revenues Slide

Canopy Growth Corp. (TSX: WEED) (Nasdaq: CGC) reported slumping revenues on Thursday and signaled a new cost-savings era that includes cutbacks on cultivation and 800 layoffs. The stock fell more than 8% in early trading on the news to lately sell at $2.52, a big drop from its year high of $9.61. Read more here.

Aurora Cannabis Revenue Boosted by Strong Euro

Aurora Cannabis Inc. (Nasdaq: ACB) (TSX: ACB) achieved positive adjusted EBITDA and reduced its debt even though it still recorded a net loss in its latest quarterly earnings. Aurora attributed the rising revenue to “growth across all cannabis business segments” as well as a full-quarter contribution of C$6.6 million from Bevo Farms. Read more here.

How Much Adult-Use Cannabis Has New York Sold? Who Knows?

While many other states quickly release sales figures for new cannabis markets, New York has been conspicuously silent. Inquiries to the New York Office of Cannabis Management and the existing stores regarding sales figures have been met with silence. Read more here.

Ayr Wellness to Exit Arizona, Expand to Ohio

Ayr Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) is exiting Arizona and turning its attention to Ohio. The multistate cannabis operator signed a definitive agreement to sell its Arizona assets, Blue Camo LLC, to AZ Goat LLC. Read more here.

Cannabis Dispensary Deals Show How Prices Are Falling

The value of a cannabis dispensary just isn’t what it used to be. Six months ago, Planet 13 (OTC: PLNHF), a Las Vegas-based marijuana company, announced it would pull the trigger on its option to buy out its social-equity partner in an Illinois cannabis dispensary in a $2.9 million transaction. By the time the deal closed yesterday, the value had dropped by $1 million because of the steep downdraft in the stocks of cannabis companies. Read more here.

In Other News

Pineapple Express Cannabis Co.

Minaro Corp. (OTC Pink: MNAO) (the “Company”), a publicly traded company, announced the execution of a share exchange, the change of its name to Pineapple Express Cannabis Company, and an application to change the company’s current ticker symbol. Read more here.

Halo Collective

Halo Collective Inc. (NEO: HALO) (OTCQB: HCANF) expanded the company’s cannabis genetics and strain portfolio within its Oregon operations. With the expansion, Halo Collective now offers a wide range of unique and rare strains, sourced from some of the top growers and breeders in the state. Read more here.

BioHarvest Sciences

BioHarvest Sciences Inc. (CSE: BHSC) (OTCQB: CNVCF) reported sales orders of $6.1 million in 2022 , representing a 160% increase over 2021. Fourth-quarter sales orders of $2.7 million were more than triple the sales orders from the same quarter in 2021. Read more here.

The post Daily Hit: February 9, 2023 appeared first on Green Market Report.

Aurora Cannabis Revenue Boosted by Strong Euro

9 February 2023 at 18:00

Aurora Cannabis Inc. (Nasdaq: ACB) (TSX: ACB) achieved positive adjusted EBITDA and reduced its debt even though it still recorded a net loss in its latest quarterly earnings, announced Thursday.

The company reported total revenues of C$61.7 million ($45.9 million), an improvement over the C$49.3 million reported in the previous quarter and C$60.6 million (1.8%) in the prior year period.

Net loss in the quarter was C$67.2 million, versus C$51.9 million in the prior quarter and C$75.1 million for the same time last fiscal year.

Aurora attributed the rising revenue to “growth across all cannabis business segments” as well as a full-quarter contribution of C$6.6 million from Bevo Farms, which the company acquired in August 2022. Cannabis revenues were up around 20% for the quarter.

Since 2021, Aurora has been trying to put itself on the path to profitability through cost cuts and high-margin medical cannabis revenue. In addition to the boost from Bevo, a strong euro beefed up European margins.

Adjusted EBITDA for the quarter was positive at C$1.4 million, versus a loss of C$7.4 million in the previous quarter and loss of C$7.1 million in the prior year period.

“We are pleased to have delivered on our commitment to achieve positive adjusted EBITDA in Q2 2023, following a tremendous effort to realize approximately $340 million of total annualized savings since February 2020,” said CEO Miguel Martin, who added that quarterly growth was primarily driven by its international medical program.

“Our Canadian rec business also demonstrated sequential growth driven by significant product innovation, and our Canadian medical cannabis business continued to benefit from strong patient relationships and high barriers to entry,” he added.

Aurora had around C$258.7 million worth of capital and wrote in its filings that the reduction of operating costs, access to a shelf prospectus to raise funds, and its current liquidity are enough to fund operating activities and cash commitments for investing, financing, and strategic moves.

“Looking ahead, we are focused on profitable growth opportunities across all segments, ongoing discipline in capital deployment, and our ability to generate positive operating cash flow as we continue to build value for shareholders,” Martin said.

The Canadian giant published its financial and operational results for the fiscal second quarter ending Dec. 31, 2022.

The post Aurora Cannabis Revenue Boosted by Strong Euro appeared first on Green Market Report.

Ayr Wellness to Exit Arizona, Expand to Ohio

By: Staff
9 February 2023 at 17:05

Ayr Wellness Inc. (CSE: AYR.A) (OTCQX: AYRWF) is exiting Arizona and turning its attention to Ohio.

The multistate cannabis operator signed a definitive agreement to sell its Arizona assets, Blue Camo LLC, to AZ Goat LLC, a group consisting primarily of the former owners of Blue Camo, who sold the business to Ayr in 2021.

The sale includes three Oasis-branded dispensaries in the greater Phoenix area, a 10,000 sq. ft. cultivation and processing facility in Chandler, an 80,000 sq. ft. cultivation facility in Phoenix, and Willcox OC LLC, a joint venture developing an outdoor cultivation facility.

Ayr will receive $20 million in cash, with additional cash proceeds from net working capital to be received within six months of closing the transaction. In addition, AZ Goat will assume lease obligations from Ayr that will result in the elimination of $15 million in long-term lease liabilities for Ayr.

Ayr will also be reducing its long-term debt obligations related to the original Blue Camo acquisition.

“Ayr’s proposed sale of Arizona assets represents the latest in a series of optimizations focused on simplifying our business and prioritizing existing and future markets where we can build depth,” said David Goubert, president at Ayr. “Today’s action allows Ayr to focus on key markets for growth and profitability, adds cash to our balance sheet, and reduces outstanding debt.”

Ayr also entered into option agreements related to two entities provisionally licensed to operate medical marijuana dispensaries in Ohio. The arrangement includes Daily Releaf’s dispensary in Riverside, Ohio, and Heaven Wellness’ in Clermont County. Neither location is operational at this time.

“Ayr is excited to invest further into the Ohio market and looks forward to establishing a fully vertical presence once permissible under Ohio regulations,” Goubert said.

In addition to the option agreements, the company entered into a support services agreement and a working capital loan agreement with Daily Releaf and Heaven Wellness.

The post Ayr Wellness to Exit Arizona, Expand to Ohio appeared first on Green Market Report.

OTC Flags Awakn Life Sciences for Stock Promotion

9 February 2023 at 15:54

Awakn Life Sciences Corp. (NEO: AWKN) (OTCQB: AWKNF) was asked by the OTC Markets group to issue an explanation behind the timing of Feb. 6 promotional emails and its stock price doubling at one point Thursday.

The OTC further requested that the company to clarify whether it has participated in what is commonly known as a “pump-and-dump” scheme, where false or misleading information is proliferated to create a buying fever that would “pump” up the price of a stock before moving to “dump” stock shares via selling their own shares at an inflated price.

“The company has not,” Awakn wrote in a Feb. 9 statement.

According to Awakn, an inquiry by management proved that “none of the company’s executive officers, directors or, to the knowledge of the company, any controlling shareholders or third party service providers, sold or purchased shares of common stock of the company within the past 90 days.”

Awakn said that it has simply continued work under an investor communications and digital marketing agreement with JRZ Capital LLC, which was disclosed in an Oct. 8, 2021, press release. JRZ Capital LLC was paid $50,000 in January this year to help send promotional emails for Awakn until the end of March.

On Monday, “OTC Markets informed the Company that it became aware of certain promotional activities concerning the Company and its common stock traded on the OTCQB Marketplace, specifically the distribution of promotional emails by third-parties, SmallCapFirm, StockWireNews, and Stock Street Wire discussing the float as well as potential catalysts of the company and summaries of recent press releases,” Awakn wrote in a Feb. 9 statement.

“The company was not involved in the creation of the materials, however has subsequently reviewed the specific details related to the company, and has confirmed these to be factual,” the company continued.

Awakn said that it is aware that the promotional activity “coincided with increased trading activity in the company’s common shares beginning on Feb. 6, 2023.”

However, the company said it didn’t believe the promotional activities were the only reason for the hike in trade volume this week, but rather attributed the increase to “currently heightened investor interest as a result of its recent press releases which disclosed that it had received ILAP approval in the U.K. as well as the initiation of an investigative study of a novel formulation of (S)-ketamine.”

Over the past year, Awakn has been contracting JRZ Capital, Geelon & Co, Just Capital Consulting, KCSA Strategic Communications, and Street Smart to aid in public relations and marketing efforts.

The post OTC Flags Awakn Life Sciences for Stock Promotion appeared first on Green Market Report.

Cannabis Dispensary Deals Show How Prices Are Falling

By: Staff
9 February 2023 at 09:56

This story was republished with permission from Crain’s Chicago and written by John Pletz

The value of a cannabis dispensary just isn’t what it used to be.

Six months ago, Planet 13 (OTC: PLNHF), a Las Vegas-based marijuana company, announced it would pull the trigger on its option to buy out its social-equity partner in an Illinois cannabis dispensary in a $2.9 million transaction. By the time the deal closed yesterday, the value had dropped by $1 million because of the steep downdraft in the stocks of cannabis companies.

Planet 13 shares are now trading at just 88 cents, compared with $1.98 on Aug. 4, when it inked the deal with entrepreneur Frank Cowan to buy out his ownership in their retail license. Cowan received $866,250 in cash, along with 1 million shares, for his 51% stake in the license.

Marijuana stocks have fallen precipitously in recent months as interest rates rose, cannabis prices fell and prospects faded for congressional action that would loosen restrictions nationally on the cannabis industry.

Deals are getting renegotiated—or scrapped. Last month, Miami-based Ayr Wellness, a publicly traded company, called off its $55 million purchase of two Chicago dispensaries operated by Dispensary 33.

The declines in stock prices and canceled deals will impact the value of 192 new retail licenses that have been issued in Illinois. Under state rules, holders haven’t been able to sell their licenses until their stores are open. At least one owner has sued to challenge those rules in a case that’s still working its way through Cook County Circuit Court.

Cowan, meanwhile, says he plans to stay with Planet 13, which is building out a dispensary in Waukegan that’s expected to open this summer. And he may well come out OK financially, given some time: He can’t sell his 1 million shares right away, due to a six-month lockup period, and the shares vest over 12 months.

The post Cannabis Dispensary Deals Show How Prices Are Falling appeared first on Green Market Report.

Canopy Slashes 800 From Payroll, to Restructure After Revenues Slide

9 February 2023 at 09:17

Canopy Growth Corp. (TSX: WEED) (Nasdaq: CGC) reported slumping revenues on Thursday and signaled a new cost-savings era that includes cutbacks on cultivation and 800 layoffs.

The stock fell more than 8% in early trading on the news to lately sell at $2.52, a big drop from its year high of $9.61.

The Canadian cannabis giant published its financial results for the third quarter ending Dec. 31, 2022.

Net revenue of $101 million in the quarter declined 28% versus the same period in the previous fiscal year. Canopy blamed the drop in revenue on several factors:

  • Increased competition in the Canadian adult-use cannabis market
  • The divestiture of C3 Cannabinoid Compound Company GmbH
  • A decline in the U.S. CBD business
  • Softer performance from Storz & Bickel and This Works.

Canopy acquired the German C3 for C$41 million in 2019 and then sold it in 2021 for C$114 million. C3 reported sales of C$53.8 million in Canopy’s 2020 fiscal year and C$62.3 million in 2021.

Cash Burn

The new restructuring also makes sense for Canopy considering historical cash burn has swelled its net losses 131% over the year to $266.7 million. Cash and short-term investments fell by a whopping $583 million to $789 million at the end of December from $1,372 million at the end of March 2022.

The company attributed this to the impact of cash used in operating activities, the first tranche of the term loan credit agreement repayment of $118 million, as well as cash used for acquisitions and investments, including the acquisition of the Verona, Virginia, manufacturing facility for BioSteel and a premium payment made to obtain an option to acquire Acreage Holdings Inc.’s outstanding debt as part of the October 2022 CUSA announcement.

Gross debt amounted to $1.2  billion on Dec. 31, 2022, an improvement over the debt level of $1.5 billion at the end of  March 2022.

“Canopy must reach profitability to achieve our ambition of long-term North American cannabis market leadership,” CEO David Klein said in a statement.These changes are difficult but necessary to drive our business to profitability and growth.”

Closing Cultivation

Canopy Growth said that it would be transitioning to an “asset-light model” in Canada by exiting cannabis flower cultivation in its Smiths Falls, Ontario, facility, ceasing the sourcing of cannabis flower from the Mirabel, Quebec, facility, and moving to a third-party sourcing model for cannabis beverages, edibles, vapes, and extracts.

The changes are in addition to multiple cost reduction activities planned for the year, including the divestiture of Canopy Growth’s Canadian retail operations, the organizational restructuring of certain corporate functions, and the closure of the Scarborough, Ontario, research facility.

The company intends to close its 1 Hershey Drive facility in Smiths Falls, Ontario, in addition to reducing headcount across the business by approximately 60%, or 800 positions. Of those, 40% are impacted immediately.

Management believes these cost reduction initiatives will reduce the annual cost of goods sold and selling, general, and administrative expenses by a combined $140 million$160 million over the next 12 months, bringing the total cost reduction target to $240 million$310 million inclusive of the reductions announced in April 2022.

Canopy Growth also said it is still committed to remaining dual–listed on the TSX and the Nasdaq as it continues pursuing its U.S. entrance strategy through Canopy USA.

“The right-sizing of our Canadian business is expected to significantly reduce our cash costs,” said CFO Judy Hong. “Canopy is firmly on the path to deliver at least quarterly breakeven adjusted EBITDA in our Canadian cannabis business in fiscal 2024, even at current revenue run-rate.”

The post Canopy Slashes 800 From Payroll, to Restructure After Revenues Slide appeared first on Green Market Report.

Irwin Naturals Signs LOI to Acquire Braxia Scientific

27 January 2023 at 13:59

Irwin Naturals Inc. (CSE: IWIN) (OTC: IWINF) has entered into a nonbinding amended and restated letter of intent to purchase medical research company Braxia Scientific Corp. (CSE: BRAX) (OTC: BRAXF) for a price tag yet to be determined.

Under the agreement, Irwin will pitch a purchase price per Braxia share based upon a valuation of the outstanding $30 million worth of Braxia shares, though the final price per Braxia share and the exchange ratio will be set forth and determined when the agreement is executed.

“We are excited to be building North America’s leading mental health and depression network under the medical expertise of Braxia’s scientific management team, including Dr. McIntyre, the world’s foremost expert in depression and ketamine research,” Irwin CEO Klee Irwin said in a statement. “This combination is a major accelerator and differentiator for Irwin’s network of Emergence clinics across the U.S. as we launch clinical research services for large pharma and emerging biotechnology companies and enhance our capacity with telemedicine capabilities.”

Klee also said the combination would give the company “access to more attractive financing, making this an attractive potential business combination for Braxia shareholders.”

The company said that the purchase price would be payable on closing by the issuance of Irwin shares to each holder of Braxia stock. Based on the closing price of Irwin shares and Braxia shares on the CSE on Jan. 25 of C$3.80 and C$0.05, respectively, the purchase price and exchange ratio imply a 315.72% premium to the price of Braxia shares.

The number of Irwin shares will also be adjusted upward in the event that the total consideration received by holders of Braxia Shares is less than $30 million, to be determined at a specified period of time after the closing date and as set forth in the agreement.

The LOI further states that the Irwin shares would be subject to a lock-up period and would be restricted from transfer or sale for a period of six months after close. Braxia insiders would be subject to a lock-up period of 12 months from the closing date.

The deal would bear out operations in several state markets in the U.S. and in Canada across three important business verticals: clinics, international clinical research services, and telehealth.

“This combination will optimize the drive for growth of mental health services, creating a first-mover advantage in many important markets in North America, while also expanding innovative drug development research to benefit from economies of scale across the businesses,” Irwin Naturals president Adam Berk.

The post Irwin Naturals Signs LOI to Acquire Braxia Scientific appeared first on Green Market Report.

Weekly Stash: January 27, 2023

27 January 2023 at 11:22

Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF) is finally exiting a trio of legacy western states in search for better profits. The exodus will begin this month with the “proactive closure of the majority of its operations” including its production and cultivation facilities in California, Colorado, and Oregon. The company cited the lack of enforcement over the illicit market and price compression as to why it was tapping out of the west coast. The company is also laying off 10% of its workforce. The company said it expects to save $60 million through the moves.

New York-based Ascend Wellness Holdings (CSE: AAWH.U) (OTCQX: AAWH) announced its expansion into Maryland with its $19 million purchase of Devi Holdings, which runs four operational medical marijuana dispensaries. The move marks the seventh state in which Ascend Wellness has a footprint, according to a press release. The company already has cannabis shops in Illinois, Massachusetts, Michigan,  New Jersey, Ohio, and Pennsylvania, according to its website.

Long-awaited federal guidance on cannabis clinical drug trials for humans has finally arrived. The guidance document from the U.S. Food and Drug Administration follows the 2018 federal farm bill, which removed cannabis with less than 0.3% THC by dry weight from the list of controlled substances. The move could dramatically accelerate the value of the CBD industry, which has been waiting on the guidance, and it could also help the industry back up some of the health claims various companies have made, which got them warning letters from the agency.

In state news…

Mississippi began its medical cannabis sales this week. The state legalized medical marijuana just a year ago. 

New York opened its first social equity applicant dispensary and the state approved 30 more retail licenses. 

In legal news this week, Nike is suing a Texas cannabis company for using the slogan “Just Hemp it”. A Michigan developer filed a $60 million lawsuit claiming delays led to a loss of funding and tenants for its project and Helping Hands Wellness Center Inc. in Nevada had its licenses suspended after inspectors “discovered Helping Hands’ employees were diverting product to the illicit market. 

As a reminder, you can now submit applications to the 2023 GMR Women’s Leadership Awards, just head over to the website and there’s a link in our Summits tab.

Next week we expect earnings from High Tide, Scotts Miracle-Gro, and MedMen.

The post Weekly Stash: January 27, 2023 appeared first on Green Market Report.

New York Forcing Cannabis Farmers to Choose Business Model

27 January 2023 at 10:28

New York’s 280 conditionally licensed recreational cannabis farmers received a notice right after Christmas from state regulators, informing them they would be required to choose one of four cultivation plans for the coming year – and that they only had a few weeks to make that decision.

The initial notice gave farmers until Jan. 13 to make a selection between growing entirely outdoors for the 2023 season, growing entirely indoors in a greenhouse, or two possible combination options of both outdoor and indoor, a major policy shift from what growers had previously understood they’d be allowed to do this year, several growers said.

After the Cannabis Association of New York (CANY) and several members who are licensed cultivators complained to the state’s Office of Cannabis Management (OCM) about the deadline, the timeline was extended, but only to Feb. 1.

The situation has many growers feeling boxed into a choice they don’t want to make and without full knowledge of the possible ramifications for their own fledgling businesses. The state still only has two retailers open and operating, and most of the legal farmers have yet to even sell any of their crops from this past fall.

“It appears to be locking us in to uninformed decisions, possibly for the next couple of years, and that’s really what has the growers concerned,” said Tim Moshier, the owner of B30 Farm in Fulton. “We haven’t been able to get our stuff to market yet and find out what sells and what doesn’t.”

Moshier pointed out that early last year, state regulators told industry stakeholders that the plan was to have multiple dispensaries open by the end of 2022, but only one – Housing Works in Manhattan – actually launched. That has nearly all of the licensed farmers still waiting to sell the vast majority of their harvests.

The new letter, Moshier said, is “one more straw on the camel’s back” for a lot of growers.

“A lot of growers thought we’d have product in dispensaries a month or two ago, according to the OCM’s original plan. That didn’t happen. People are getting cash-strapped now,” he said.

It’s also unclear whether farmers will be permanently locked into whatever choice they make, or if regulators will allow them the flexibility to, say, add a greenhouse to an outdoor-only grow down the line at some point or transition into a vertically integrated microbusiness.

Those are both changes that several farmers have been seriously contemplating.

“We all had the idea we’d be in the place where we’re at until 2024, and then we’d be able to at least make an educated decision based on the market conditions and based on a good perspective of what our place can really be here to be successful,” said Brittany Carbone, the CEO of Tricolla Farms in Berkshire and a board member of CANY, which represents about 80 of the state-licensed farmers.

“To make that decision now is just very hasty,” Carbone said. “For a vast majority, it’s a very difficult decision to make at such an uncertain time.”

The Options

The four choices growers were given are:

  • Outdoor, which includes up 43,560 square feet of outdoor canopy.
  • Greenhouse/mixed light with no more than 20 lights, which includes 25,000 square feet of canopy.
  • Outdoor and greenhouse/mixed light with no more than 20 lights, which allows for both indoor and outdoor cultivation, with a cap of 20,000 square feet of greenhouse canopy and 30,000 square feet of total canopy.
  • Outdoor and greenhouse/mixed light with no restriction on the number of grow lights, with a cap of 12,000 square feet of outdoor canopy and 6,250 square feet in a greenhouse.

“This form is required to be submitted by all (adult use conditional cultivators) that wish to cultivate in the 2023 season,” the letter from the OCM to growers reads.

The letter also includes a provision that any grower who signs and submits the form recognizes that the “selected and approved cultivation tier on this form will transition with conditional licensees as their approved tier for full licensure,” which suggests that whatever choice the growers all make will become their long-term place in the New York cannabis supply chain.

“The more indoor you’re allowed to have, then the less outdoor. It’s strange, and there’s no guidance for it,” said Tess Interlicchia, CEO and owner of Grateful Valley Farm in Corning.

The Problems

Interlicchia said it feels as though the OCM is putting more restrictions on small distressed farms like hers, instead of giving them ways to be competitive, even though the New York market has been specifically designed to bolster small businesses. The 280 conditional cultivation licenses, for instance, were all given to licensed hemp farmers, with larger multistate operators being forced to largely sit on the sidelines until late 2025.

But once bigger companies can enter the market, Interlicchia said, the choice she and other farmers are being forced to make this coming week could come back to haunt them.

“It feels like we’re being set up to fail, to be honest, because none of us have tens of millions of dollars to throw up a greenhouse right away to be able to compete with the MSO’s,” said Interlicchia, who added she’s still struggling with which of the four options to choose. “It’s nerve wracking. It’s kind of scary.”

OCM spokespeople did not respond to multiple requests for comment on the policy shift, and the reason for the notice remains unclear.

“I would love to know” why the OCM sent out the notice, Interlicchia said. “They have sent out plenty of surveys. They could have just done that, instead of being like, ‘This is firm and you must do this by that date.'”

Carbone said she believes the policy shift is an attempt by the OCM to both get a better handle on overseeing the statewide supply chain and to address a prior CANY complaint that 20 lights for a greenhouse is too few lamps for indoor growers to be truly effective.

“They did provide a pathway for people to utilize more lights, to extend that season and greenhouse production,” Carbone noted. “It’s something that’s needed. But once again, it’s a lack of clarity, and communication not being as dynamic as we’d like it to be. It’s causing a lot of frustration for growers.”

“There are definitely people who are like, ‘F*** yeah, like, I have the greenhouse, I’m filling it out with lights.’ They’re ready to go. And that’s awesome, we need that,” Carbone said, but characterized that as a minority of farmers.

Moshier said he’s still hopeful that regulators will want to work with the farmers instead of being hard-nosed about the situation, but he added that the fundamental issue is a lack of communication.

“I think there’s a 50/50 chance they may extend the (Feb. 1) deadline again, and maybe come back with some more clarification,” Moshier said. “Hopefully they’ll allow us a little more latitude. I don’t know what’s driving the OCM, to need this information this early in the season.”

The post New York Forcing Cannabis Farmers to Choose Business Model appeared first on Green Market Report.

Ayr Wellness Dips On Dispensary 33

27 January 2023 at 08:39

Ayr Wellness Inc. (CSE: AYR.A)(OTCQX: AYRWF) is killing its plan to buy Chicago-based Gentle Ventures also known as Dispensary 33. According to the company statement, Ayr will no longer be required to pay the previously announced purchase consideration of $55 million upfront, including $12 million of cash, $3 million of seller notes, and $40 million of stock.

“The cannabis market has changed significantly in the 15 months since we agreed to acquire Dispensary 33. Both parties have acknowledged this reality and engaged in good faith dialogue as we came to the mutual decision to terminate the proposed arrangement,” said David Goubert, President at Ayr. “We are focused on optimizing our business and will prioritize our efforts in markets where we can build meaningful depth and drive strong revenue and cash flow in the near term. Additional plans for optimization include implementation of operating efficiencies, lowering costs across our business, and reorienting our investments into the markets, segments and activities that are most impactful for our growth and profitability.”

Expansion Continues

The company hasn’t slowed its expansion. It recently opened two new retail locations in Florida: Tarpon Springs and Orlando. Both stores feature the AYR retail design concept and operate under the Liberty Health Sciences banner. The new stores offer many of Ayr’s national brands and products and feature a “bud bar,” providing customers with a sensory experience showcasing samples of whole flower strains currently available for purchase.

In New Jersey, its three retail locations, formerly known as Garden State Dispensary, are now operating under the AYR dispensary name. Since acquiring Garden State Dispensary in September 2021, Ayr said it has made significant progress in elevating key facets of the business, including improvements to the menu and overall retail experience. In 2022 the company opened a large-scale cultivation expansion, launched adult-use sales at its three retail locations, the maximum allowed in the state, and introduced its national brand portfolio in the wholesale market and its retail stores.

Latest Earnings

Ayr Wellness reported its third-quarter earnings in November revenue rose 24% to $119 million over last year’s revenue of $96 million and an increase of 8.6% sequentially. The operating loss grew to $20.7 million over last year’s loss of $8.9 million. It improved by 17% over the second quarter. The company had a comfortable cash cushion of $100 million.

 

The post Ayr Wellness Dips On Dispensary 33 appeared first on Green Market Report.

The Road to New York’s Potentially Massive Cannabis Market

27 January 2023 at 00:30

Graffiti in New York

The New York state cannabis market is projected to be one of the biggest in the world, with some industry estimates forecasting sales to surpass $2 billion within just a few years. But the state’s recreational industry is just starting to get off the ground, with multiple players eyeing how to break in and make money.

The city’s first state-sanctioned adult-use dispensary opened in December, and its second – but first social-equity licensed store – just opened this week. Meanwhile, smoke shops are popping up on seemingly every corner, and medical marijuana dispensaries are holding on to prime real estate as both await what they hope will be their turn in the licensing process.

This month, Green Market Report joined forces with our sister publication Crain’s New York to take a closer look at the rollout:

We also asked some of the various stakeholders to share their thoughts on where the rollout is – and where they think it should go. Contributors include:

This package really is just a snapshot of an evolving market and industry – one that we’ll be keeping a close eye on in the weeks and months to come.

Thanks to Telisha Bryan, managing editor of Crain’s New York, and her team for helping us create this package for you, and to Buck Ennis for capturing the industry in pictures.

The post The Road to New York’s Potentially Massive Cannabis Market appeared first on Green Market Report.

Potency Tax Could be a Major Buzzkill for Sanctioned Cannabis Retailers

27 January 2023 at 00:26

This story was written in partnership with Crain’s New York, the trusted voice of the New York business community. 

One of the most controversial aspects of New York’s new recreational cannabis market is its tax system, which some have worried will undermine licensed businesses by driving consumers to cheaper underground dealers.

A white paper published in December by a pair of New York tax attorneys, just weeks before the formal start of recreational marijuana sales on Dec. 29, warned of that very possibility. It predicted—and was proven accurate after sales launched—that a legal eighth of cannabis flower in New York with 30% THC would cost about $75.

Prices at Housing Works—the first state-sanctioned cannabis retailer in the five boroughs—proved to be not far below that, with prices fluctuating because taxes are based on THC potency. According to the nonprofit’s online menu, an eighth of cannabis flower ranges in price and potency from 19% THC for $40 to 27% for $60. With the 13% excise tax added, out-the-door prices would be between $45 and $68, respectively.

But if customers remain price-sensitive, as data from other mature recreational marijuana markets suggest, then they’ll broadly be willing to pay only as much as 10% to 15% above prices on the unregulated market, according to the paper, authored by attorneys Jason Klimek and James Mann.

By contrast, unlicensed street vendors in New York City last month were peddling cannabis eighths for between $10 and $45, Green Market Report found.

Combine that with overall lax enforcement to date against the underground market, and the situation has the potential to undercut state-licensed retailers—particularly smaller and less-capitalized businesses—before they can truly get off the ground, Klimek and Mann asserted.

Charles King, CEO of Housing Works / photo by Buck Ennis

Charles King, the CEO of Housing Works, said in early January that he doesn’t think the situation is that dire, and companies such as his will be able to survive as long as they stick to a solid retail business plan and tap the immense tourism market.

“I think people know that you’re paying for quality, you’re paying for the taxes and all the rest of what goes with the regulated, licensed market,” King said.

Still, there will have to be more of a focus on enforcement against illicit competition by state authorities, King said.

It’s a big undertaking, as many illicit operators already have brand recognition by offering legally produced but illegally shipped cannabis from California and Oregon, such as the famed SoCal brand Jungle Boys. That’s one brand name New York City resident Joe Lustberg, managing partner at Upwise Capital, said he ran into recently at a smoke shop.

“For some cannabis operator who’s competing with the smoke shop next door [that is] able to sell California eighths for $30 [and] that’s better weed than what they’re selling at Housing Works, it’s tough,” Lustberg said.

The tax structure also might be altered by the Legislature, because making the system more business-friendly is a top priority of industry interests in Albany, including for the Cannabis Association of New York.

“I do feel confident that the state is very much aware of the issue with the potency tax and, at the very least, open to reform,” said Brittany Carbone, a board member of CANY and a cannabis farmer upstate. “It’s been well proven that more reasonable tax structures actually result in higher rates of purchase in legal dispensaries, which results in a net positive win for the state, in terms of tax revenues.”

Even if the tax structure doesn’t change, cannabis attorney Lauren Rudick said, the THC-based potency tax will probably encourage the creation and sale of a more diverse range of cannabinoid products that don’t rely only on THC to please consumers. And that could be just what the burgeoning industry needs: more product variety.


By the Numbers:

$68

Highest price, with taxes added, for an eighth of cannabis with 27% THC sold at Housing Works

$10

Lowest price for an eight of cannabis bought on the street

The post Potency Tax Could be a Major Buzzkill for Sanctioned Cannabis Retailers appeared first on Green Market Report.

As Rec Sales Start, Medical Marijuana Firms Left Warming the Bench

27 January 2023 at 00:25

This story was written in partnership with Crain’s New York, the trusted voice of the New York business community. 

When New York gave the sale and use of medical marijuana the green light, officially permitting it in 2014, the firms that vied for a spot as one of the state’s 10 vertically licensed operators envisioned the true golden ticket to be early entry into the eventual recreational cannabis retail market.

That expectation was amplified when the state passed the Marijuana Regulation and Taxation Act in 2021. Investment dollars poured in, and medical licenses traded at high valuations on the secondary market, bolstered by the idea that those who bought in early would be able to capitalize on both adult-use and medical retail sales, cultivation and manufacturing.

However, under draft regulations released in November, those companies will have to wait at least three years from the official launch date of adult-use sales just to apply for a recreational retail permit. Final rules have yet to be published.

“They were hit with a bait and switch by the state regulators,” said Tom Adams, principal analyst and CEO of Global Go. “You know, ‘Come to our state and help apply your expertise and your capital to building out this incredibly limited medical-­only market that you’re clearly not going to make any money at anywhere in New York.’”

The Columbia Care medical marijuana dispensary near Union Square in Manhattan. / photo by Buck Ennis

So the multistate operators came.

The proposed rules, however, also established a two-tier system that prohibits growers and manufacturers from participating on the retail side—and vice versa. That means those same players who helped establish the medical cannabis industry “got sort of the back of the hand from regulators” and now must accept that they cannot implement the business models they’ve used in other states, Adams said.

Those who invested in medical operations in New York early on expected, if not “the first bite at the apple … at least a first bite at the same time as the other licensees for some of these retail adult-use licenses,” said Brandon Kurtzman, a partner at cannabis law firm Vicente Sederberg.

Both Adams and Kurtzman said the pivot now is to develop product brands through the cultivation and manufacturing side to sell to retailers and social consumption lounges.

Boxed in

The $138.9 million write-down Toronto-­based RIV Capital took after its acquisition of New York’s Etain, one of the 10 local medical cannabis license holders, illustrates the conundrum. RIV Capital agreed to pay $212 million in cash and $35 million in stock for the small, women-led medical cannabis company.

But instead of being able to capitalize on its existing business structure, Etain has been forced into a single channel. With heavy investment already sunk into cultivation, the company appears to be boxed into being a grower—the less lucrative side of the cannabis business.

The price paid for Etain was so troubling to RIV Capital’s largest shareholder, JW Asset Management, that the firm asked for a special meeting of shareholders to replace five of the seven directors on RIV’s board.

In New York, Adams said, having a brand on store shelves “is probably more valuable than anything else” an operator can do, as there is not much real brand dominance yet among the plethora of cannabis companies out there.

Despite the firms seemingly being last in line, nothing is completely set in stone.

“It’ll be very interesting to see what happens with these draft regulations, see what the comments look like and if there’s going to be any compromise between what they put out [and] what [medical operators] are looking for in this market,” Kurtzman noted.

“The goal here is to provide access to consumers,” he added. “I think you do that by allowing new licensees but also allowing the existing licensees to participate, because that’s more or less what you told them they were going to be able to do in the law.”

The post As Rec Sales Start, Medical Marijuana Firms Left Warming the Bench appeared first on Green Market Report.

New York’s Cannabis Market Faces Uphill Climb as Adult-Use Sales Begin

27 January 2023 at 00:25

This story was written in partnership with Crain’s New York, the trusted voice of the New York business community. 

The New York state cannabis market is projected to be one of the biggest in the world, with some industry estimates forecasting sales to surpass $2 billion within just a few years. But the slow rollout and uncertain regulations—after all, the rules are still in draft form—leave many wondering if a large chunk of sales will continue going to unlicensed dealers.

On top of that, the state’s unclear timeline for when licenses will be issued and storefronts will be fully operational as well as concerns about how much consumers will be willing to spend once potency and excise taxes are baked in, among other hurdles, have given some stakeholders pause about how successful smaller players will be in the market.

“This is a very optimistic time, but the business owner in me is very stressed out every single day on how I’m actually going to make this work,” said Brittany Carbone, a board member of the Cannabis Association of New York and the CEO of Tricolla Farms, near Ithaca. “There could be thousands of millionaires rather than a few billionaires created through the New York market, and the first step is getting more people licensed.”

Cultivation licenses were the first to be issued, but they were restricted to existing hemp farmers who could convert to growing marijuana to supply product rich in THC, the chemical that provides users with the sensation of being high, when the adult-use market launched.

There’s a long way to go, however. As of early January, the New York Office of Cannabis Management had awarded 354 conditional licenses, made up of 279 growers, 39 processors and 36 retailers, on top of the 10 registered organizations, or ROs, that are allowed to sell medical cannabis.

That includes 26 new adult-use retail licenses for four of New York City’s boroughs and Long Island. (Brooklyn was one of five regions where licensing has been delayed by litigation.) Each of those licensees can open three stores.

In addition, Manhattan, Queens, the Bronx, Brooklyn and Staten Island are already home to eight medical dispensaries, including three in Brooklyn.

It’s not clear when authorities will grant more permits; 903 applications were filed for the first round of retail licenses alone last year, so timing is a major question mark.

Not only that, but the sheer price difference between the first legal retailer in New York thus far Manhattan’s — Housing Works — and the enormous number of unlicensed dealers have some fearing that many companies won’t survive.

“It is an uphill battle, but again, it’s always an uphill battle when you don’t have massive capital, no matter what industry you’re in. But when you throw in the illicit market side, it makes it even harder,” attorney Jason Klimek, a member of the New York Bar Association’s cannabis law section, said when asked how he thinks the market—which is centered on small mom-and-pop businesses—will perform.

The most immediate obstacle for many New York cannabis hopefuls is getting licensed and operational, but the timeline on that front is painfully unclear.

The state has no limit on the number of business permits it will award—in theory—but regulators have been painstakingly slow on that front, particularly for retailers. The first round, which is so far only partially completed, will award 175 retail permits, including 150 for “justice-involved” individuals and an additional 25 for nonprofits.

The longer those retailers have to wait, the closer they’ll get to the three-year deadline, at the end of 2025, when the 10 multistate operator ROs will be allowed to fully enter the recreational cannabis side of the market. For now those behemoths are relegated to wholesaling cannabis products to licensed adult-use firms.

Most industry observers agree that the 10 will likely start dominating quickly because they’ve got an edge that no other retailer will have: vertical integration, their own in-house supply chains and branded product lines.

All the other retailers are prohibited from building such infrastructure or even having their own brands—another complaint of some license hopefuls.

“That is not good, because the only way we can level the playing field is for the smaller players like myself … to be able to support each other and be able to have each others’ products. The way the regulations are set up, I don’t think we could do that,” said Vladimir Bautista, CEO of New York City–based cannabis lifestyle brand Happy Munkey, one of the contenders for a retail license.

There’s even more uncertainty about the licensing rollout because of ongoing litigation that has held up at least 18 retail licenses thus far and has the potential to delay the permitting even more.

The post New York’s Cannabis Market Faces Uphill Climb as Adult-Use Sales Begin appeared first on Green Market Report.

Your Take: NY’s Cannabis Market Isn’t Moving Too Slowly — It’s on a Mission

By: Staff
27 January 2023 at 00:23

This story was written in partnership with Crain’s New York, the trusted voice of the New York business community. 

by Dasheeda Dawson, Cannabis NYC

Dasheeda Dawson, Cannabis NYC

It took nearly a century to suppress the legacy of cannabis in American agriculture and medicine. Just a decade ago, as a Brooklyn native who grew up during the height of cannabis criminalization, I could not have imagined buying an eighth of weed legally in New York City.

Despite the history, on March 31, 2021, the Marijuana Regulation and Taxation Act, championed by Assembly Majority Leader Crystal Peoples-Stokes, state Sen. Liz Krueger and the StartSMART Coalition, became the country’s landmark equity-centered law to intentionally hold government accountable for restoring and repairing communities disproportionately impacted by the overpolicing and disinvestment of the prohibition era.

I never expected the damage from decades of harsh laws and entrenched negative stigmas to disappear overnight. However, some have criticized the state’s timing, peddling the narrative that it is moving too slowly.

Analyzing the adult-use markets legalized prior to New York’s, every state had a lag period between legalization and launch, more often giving first access to already licensed medical operators, which further exacerbated inequities in the industry. In 2016 California and Massachusetts legalized adult use, and both opened the market for sales in 2018. In 2020 New Jersey legalized cannabis, and the state opened the market for first sales in 2022.

Providing 300-plus licenses to justice-involved individuals, small-business owners and farmers, the New York state Office of Cannabis Management should be commended for rapidly building a seed-to-shelf supply chain in less than two years, culminating with the first dispensary opening in December 2022.

New York is also taking an unprecedented approach to support previously existing, unlicensed cannabis entrepreneurs, often referred to as “legacy operators,” transition into the legal industry. Though others demonized the legacy market, New York has embraced the underground culture and its credibility.

The state’s conditional adult-use retail dispensary license and Cannabis Compliance Training and Mentorship Program mark the start of intentional inclusion in New York’s market. The nonprofit CAURD licensing opportunity also demonstrates an extraordinary model that supports sustainable funding to organizations that have served marginalized communities, provides opportunities to those same communities for retail workforce development and contributes to state cannabis tax revenue, 40% of which goes back to the communities disproportionately impacted by criminalization.

Amid these groundbreaking advancements for the state, New York City is contending with the proliferation of visible, unlicensed smoke shops, a common trend experienced during the lag period in other markets. From my experience in legalization efforts across the country, an industry grounded in restorative justice requires a three-pronged approach to enforcement:

  1. Facilitating the transition of preexisting legacy operators into the legal market through intentional programming and resources;
  2. Bringing unlicensed businesses that have received warnings into compliance through rehabilitative engagement; and,
  3. Using civil enforcement actions to disrupt unregulated activities that pose a risk to public health and safety.

Mayor Eric Adams launched Cannabis NYC to support New Yorkers starting or growing a legal cannabis-related business. As an emerging multibillion-dollar industry, cannabis will contribute significantly to the city’s economic recovery and can address the past wrongs that disproportionately affected Black and brown communities.

Cannabis NYC is on a mission to make our city the global leader in cannabis industry excellence in education and equity across business, science and culture. To accomplish this, MRTA’s intent must be protected, and efforts to repair social, economic, environmental and human injuries caused by prohibition must not be derailed by stigma and misinformation.

Cannabis NYC is actively creating an interagency hub of free resources and services for all New Yorkers, kicking off with a five-borough informational tour, in collaboration with the New York City Housing Authority and the Mayor’s Office of Equity. We are partnering with industry pioneers and institutions to support citywide public education initiatives, workforce training and curriculum development. The NYC Cannabis Policy Advisory Commission will include a diverse group of local and global experts, including racial justice, economic development and health equity leaders tasked with publishing an annual policy report. This is just the beginning.

Cannabis is a plant with agricultural, industrial, nutritional, medical and spiritual utilities that will have global impact, from health to hospitality to housing. Armed with the right alignment of community advocacy, business innovation and government leadership, at the state and local level, New York is poised to become a model of cannabis excellence for the world.

Dasheeda Dawson is founding director of Cannabis NYC.

The post Your Take: NY’s Cannabis Market Isn’t Moving Too Slowly — It’s on a Mission appeared first on Green Market Report.

❌
❌